Benjian Gao,1– 3,* Jia Luo,4,* Ying Liu,1– 3,* Song Su,1– 3 Shaozhi Fu,4 Xiaoli Yang,1– 3 Bo Li1– 3 1Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China; 2Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan Province, People’s Republic of China; 3Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan Province, People’s Republic of China; 4Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China*These authors contributed equally to this workCorrespon...
Shengnan Huang,1,* Chunming Li,2,* Weiping Wang,1 Huanjie Li,1 Zhi Sun,3 Chengzhi Song,4 Benyi Li,5 ...
International audienceBackground: Doxorubicin Transdrug (DT), a nanoformulation of doxorubicin, was ...
The objective of the present study was to develop 2-hydroxypropyl methacrylate-co-polyethylene metha...
Xingang Liu,1 Jianmeng Wang,2 Weiguo Xu,3 Jianxun Ding,3 Bo Shi,4 Kexin Huang,4 Xiuli Zhuang,3 ...
Huan-huan Wang,1,* Zhi-guang Fu,1,* Wei Li,2 Yun-xia Li,1 Li-sheng Zhao,1 Li Wen,1 Jian-jun Zhang,2 ...
Min Li,1 Weiyue Zhang,2 Birong Wang,3 Yang Gao,1 Zifang Song,1 Qi Chang Zheng1 1Department of Hepat...
Mengfei Ji,1,* Xiaojing Qiu,2,* Lin Hou,1 Shengnan Huang,1 Yuanmin Li,1 Yang Liu,1 Shaofeng Duan,3,4...
Dazhong Chen,1–3,* Xiaoli Pan,4,* Fangyuan Xie,5,* Ying Lu,2 Hao Zou,2 Chuan Yin,6 Yu Zhang,7 ...
Wendu Duan, Yan Liu Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, B...
Introduction: Among the many anticancer drugs used clinically, doxorubicin (Dox), was one of widely ...
Haijun Shen,1 Qianqian Gao,1 Qi Ye,1 Shiyun Yang,1 Yuqian Wu,1 Qin Huang,1 Xiaona Wang,2 Zhenhua Sun...
Wanlin Tan,1,2 Chen Sijie,1,2 Yan Xu,1,2 Mingyu Chen,1,2 Haiqin Liao,1,2 Chengcheng Niu1,2 1Departme...
Hepatocellular carcinoma (HCC) is the 5th most commonly-occurring cancer worldwide and the 2nd highe...
Tianfeng Yang,1,* Guowen Du,2,* Yuxin Cui,1 Runze Yu,1 Chen Hua,2 Wei Tian,2,3 Yanmin Zhang1 1Schoo...
Cancer is one of the leading causes of death worldwide with approximately 14 million new cases repor...
Shengnan Huang,1,* Chunming Li,2,* Weiping Wang,1 Huanjie Li,1 Zhi Sun,3 Chengzhi Song,4 Benyi Li,5 ...
International audienceBackground: Doxorubicin Transdrug (DT), a nanoformulation of doxorubicin, was ...
The objective of the present study was to develop 2-hydroxypropyl methacrylate-co-polyethylene metha...
Xingang Liu,1 Jianmeng Wang,2 Weiguo Xu,3 Jianxun Ding,3 Bo Shi,4 Kexin Huang,4 Xiuli Zhuang,3 ...
Huan-huan Wang,1,* Zhi-guang Fu,1,* Wei Li,2 Yun-xia Li,1 Li-sheng Zhao,1 Li Wen,1 Jian-jun Zhang,2 ...
Min Li,1 Weiyue Zhang,2 Birong Wang,3 Yang Gao,1 Zifang Song,1 Qi Chang Zheng1 1Department of Hepat...
Mengfei Ji,1,* Xiaojing Qiu,2,* Lin Hou,1 Shengnan Huang,1 Yuanmin Li,1 Yang Liu,1 Shaofeng Duan,3,4...
Dazhong Chen,1–3,* Xiaoli Pan,4,* Fangyuan Xie,5,* Ying Lu,2 Hao Zou,2 Chuan Yin,6 Yu Zhang,7 ...
Wendu Duan, Yan Liu Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, B...
Introduction: Among the many anticancer drugs used clinically, doxorubicin (Dox), was one of widely ...
Haijun Shen,1 Qianqian Gao,1 Qi Ye,1 Shiyun Yang,1 Yuqian Wu,1 Qin Huang,1 Xiaona Wang,2 Zhenhua Sun...
Wanlin Tan,1,2 Chen Sijie,1,2 Yan Xu,1,2 Mingyu Chen,1,2 Haiqin Liao,1,2 Chengcheng Niu1,2 1Departme...
Hepatocellular carcinoma (HCC) is the 5th most commonly-occurring cancer worldwide and the 2nd highe...
Tianfeng Yang,1,* Guowen Du,2,* Yuxin Cui,1 Runze Yu,1 Chen Hua,2 Wei Tian,2,3 Yanmin Zhang1 1Schoo...
Cancer is one of the leading causes of death worldwide with approximately 14 million new cases repor...
Shengnan Huang,1,* Chunming Li,2,* Weiping Wang,1 Huanjie Li,1 Zhi Sun,3 Chengzhi Song,4 Benyi Li,5 ...
International audienceBackground: Doxorubicin Transdrug (DT), a nanoformulation of doxorubicin, was ...
The objective of the present study was to develop 2-hydroxypropyl methacrylate-co-polyethylene metha...